Valencia, CA – According to filings with the U.S. Securities and Exchange Commission, SetPoint Medical is raising $20,500,000.00 in a new round of investment. Sources indicate as part of senior management President and Chief Executive Officer, Murthy Simhambhatla played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About SetPoint Medical

SetPoint Medical is developing novel bioelectronic medicine therapies to treat those who suffer from autoimmune diseases such as rheumatoid arthritis, Crohn’s Disease and multiple sclerosis.  The company has developed a proprietary and innovative bioelectronic medicine platform consisting of a micro-regulator programmed via a unique prescription pad based interface.  This novel therapy has the potential to provide patients and healthcare providers with a safe and efficacious alternative to drugs, while costing payers significantly less than  biologic therapies.

To learn more about SetPoint Medical, visit http://www.setpointmedical.com/

Contact:
Murthy Simhambhatla, President and Chief Executive Officer
661-750-6140
msimhambhatla@setpointmedical.com
https://www.linkedin.com/in/murthy-simhambhatla-884668bb/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved